Skip to main content
Log in

Radiofrequency Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

  • Myocardial Disease (A Abbate, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable form of cardiomyopathy, typically with autosomal dominant transmission, shown to be a defect in the cardiac desmosomes, with distinct regional and histopathological features. Clinically, this can ultimately result in bi-ventricular failure and/or malignant ventricular tachycardia (VT) via reentrant circuits created by patchy scar formation. We sought to review the current treatment for ventricular arrhythmias in the setting of ARVC, with particular attention to radiofrequency (RF) ablation and its varied techniques, along with potential therapies in the ablation spectrum.

Recent Findings

There is underwhelming data on the effectiveness of medical therapy for ARVC-related VT, including beta-blockers and antiarrhythmic medication. Primary and secondary prophylactic implantable-cardioverter defibrillator (ICD) implantation in higher-risk patients is recommended. More recently, RF ablation has been used for ARVC-related VT. Endocardial VT ablation in this setting can produce acute success, though recurrence rate is quite high, which may be explained by the more epicardial and patchy nature of the disease. Combined endocardial-epicardial ablation has since been shown to be feasible, safe, and with significantly better acute and long-term success, particularly when combined with scar dechanneling or homogenization of the scar. However, recurrence rates are not insignificant, and ablation does not eliminate the need for ICD placement.

Summary

Medical therapy for ARVC-related VT is suboptimal. RF ablation techniques including endocardial and epicardial approaches appear to have the highest success rates for ARVC-related VT. Catheter ablation of VT in ARVC patients should be considered a potentially effective strategy for eliminating frequent VT episodes and ICD shocks rather than a curative therapeutic approach, until long-term efficacy has been consistently documented. Research into the optimal mapping and ablation techniques are promising and ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Manyari DE, Klein GJ, Gulamhusein S, Boughner D, Guiraudon GM, Wyse G, et al. Arrhythmogenic right ventricular dysplasia: a generalized cardiomyopathy? Circulation. 1983;68:251–7.

    Article  CAS  PubMed  Google Scholar 

  2. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384–98.

    Article  CAS  PubMed  Google Scholar 

  3. Fontaine G, Frank R, Guiraudon G, Pavie A, Tereau Y, Chomette G, et al. Significance of intraventricular conduction disorders observed in arrhythmogenic right ventricular dysplasia. Arch Mal Coeur Vaiss. 1984;77:872–9.

    CAS  PubMed  Google Scholar 

  4. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533–41.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lemery R, Brugada P, Janssen J, Cheriex E, Dugernier T, Wellens HJ. Nonischemic sustained ventricular tachycardia: clinical outcome in 12 patients with arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol. 1989;14:96–105.

    Article  CAS  PubMed  Google Scholar 

  6. Romero J, Mejia-Lopez E, Manrique C, Lucariello R. Arrhythmogenic right ventricular cardiomyopathy (ARVC/D): a systematic literature review. Clin Med Insights Cardiol. 2013;7:97–114.

    PubMed  PubMed Central  Google Scholar 

  7. Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376:61–72.

    Article  CAS  PubMed  Google Scholar 

  8. Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation. 2006;113:1634–7.

    Article  PubMed  Google Scholar 

  9. Kamath GS, Zareba W, Delaney J, Koneru JN, McKenna W, Gear K, et al. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2011;8:256–62.

    Article  PubMed  Google Scholar 

  10. Hoffmayer KS, Bhave PD, Marcus GM, James CA, Tichnell C, Chopra N, et al. An electrocardiographic scoring system for distinguishing right ventricular outflow tract arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy from idiopathic ventricular tachycardia. Heart Rhythm. 2013;10:477–82.

    Article  PubMed  Google Scholar 

  11. Dechering DG, Kochhauser S, Wasmer K, Zellerhoff S, Pott C, Kobe J, et al. Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2013;10:158–64.

    Article  PubMed  Google Scholar 

  12. Gerlis LM, Schmidt-Ott SC, Ho SY, Anderson RH. Dysplastic conditions of the right ventricular myocardium: Uhl’s anomaly vs arrhythmogenic right ventricular dysplasia. Br Heart J. 1993;69:142–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wichter T, Breithardt G. Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: a role for genotyping in decision-making? J Am Coll Cardiol. 2005;45:409–11.

    Article  PubMed  Google Scholar 

  14. European Heart Rhythm A, Heart Rhythm S, Zipes DP, Camm AJ, Borggrefe M, Buxton AE, et al. American College of C, American Heart Association Task F and European Society of Cardiology Committee for Practice G. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48:e247–346.

    Article  Google Scholar 

  15. Leclercq JF, Coumel P. Characteristics, prognosis and treatment of the ventricular arrhythmias of right ventricular dysplasia. Eur Heart J. 1989;10(Suppl D):61–7.

    Article  PubMed  Google Scholar 

  16. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86:29–37.

    Article  CAS  PubMed  Google Scholar 

  17. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al. Multidisciplinary study of right ventricular dysplasia I. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. 2009;54:609–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ermakov S, Gerstenfeld EP, Svetlichnaya Y and Scheinman MM. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2016.

  19. Hodgkinson KA, Parfrey PS, Bassett AS, Kupprion C, Drenckhahn J, Norman MW, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol. 2005;45:400–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108:3084–91.

    Article  PubMed  Google Scholar 

  21. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011;58:1485–96.

    Article  PubMed  Google Scholar 

  22. Epstein AE, JP DM, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. American College of Cardiology/American Heart Association Task Force on Practice G, American Association for Thoracic S and Society of Thoracic S. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408.

    Article  PubMed  Google Scholar 

  23. Dalal D, Jain R, Tandri H, Dong J, Eid SM, Prakasa K, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50:432–40.

    Article  PubMed  Google Scholar 

  24. Marchlinski FE, Zado E, Dixit S, Gerstenfeld E, Callans DJ, Hsia H, et al. Electroanatomic substrate and outcome of catheter ablative therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy. Circulation. 2004;110:2293–8.

    Article  PubMed  Google Scholar 

  25. • Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2009;120:366–75. This is the first study that demontrate the benefit of epicaridal ablation for ARVD patients.

    Article  PubMed  Google Scholar 

  26. Fontaine G, Frank R, Rougier I, Tonet JL, Gallais Y, Farenq G, et al. Electrode catheter ablation of resistant ventricular tachycardia in arrhythmogenic right ventricular dysplasia: experience of 13 patients with a mean follow-up of 45 months. Eur Heart J. 1989;10(Suppl D):74–81.

    Article  PubMed  Google Scholar 

  27. Ellison KE, Friedman PL, Ganz LI, Stevenson WG. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol. 1998;32:724–8.

    Article  CAS  PubMed  Google Scholar 

  28. Polin GM, Haqqani H, Tzou W, Hutchinson MD, Garcia FC, Callans DJ, et al. Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2011;8:76–83.

    Article  PubMed  Google Scholar 

  29. Pokushalov E, Romanov A, Turov A, Artyomenko S, Shirokova N, Karaskov A. Percutaneous epicardial ablation of ventricular tachycardia after failure of endocardial approach in the pediatric population with arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2010;7:1406–10.

    Article  PubMed  Google Scholar 

  30. Bai R, Di Biase L, Shivkumar K, Mohanty P, Tung R, Santangeli P, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol. 2011;4:478–85.

    Article  PubMed  Google Scholar 

  31. •• Berruezo A, Fernandez-Armenta J, Mont L, Zeljko H, Andreu D, Herczku C, et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol. 2012;5:111–21. In this study a detailed description of how to perform scar dechannelling in ARVD patients is given.

    Article  PubMed  Google Scholar 

  32. Fernandez-Armenta J, Andreu D, Penela D, Trucco E, Cipolletta L, Arbelo E, et al. Sinus rhythm detection of conducting channels and ventricular tachycardia isthmus in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2014;11:747–54.

    Article  PubMed  Google Scholar 

  33. Philips B, te Riele AS, Sawant A, Kareddy V, James CA, Murray B, et al. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2015;12:716–25.

    Article  PubMed  Google Scholar 

  34. Santangeli P, Zado ES, Supple GE, Haqqani HM, Garcia FC, Tschabrunn CM, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8:1413–21.

    PubMed  Google Scholar 

  35. Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512–20.

    Article  CAS  PubMed  Google Scholar 

  36. Berte B, Denis A, Amraoui S, Yamashita S, Komatsu Y, Pillois X, et al. Characterization of the left-sided substrate in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8:1403–12.

    PubMed  Google Scholar 

  37. •• Corrado D, Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. 2015;132:441–53. This is the most updated consensus statement with precise recommendations for RF ablation in ARVD patients.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Te Riele AS, Ajijola OA, Shivkumar K, Tandri H. Role of bilateral sympathectomy in the treatment of refractory ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9:e003713.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Luigi Di Biase.

Ethics declarations

Conflict of Interest

Dr. Di Biase is a consultant for Stereotaxis, Biosense Webster, Boston Scientific, and St. Jude Medical and has received speaker honoraria/travel from Medtronic, Janssen, Pfizer, EPiEP, and Biotronik.

Dr. Natale has received speaker honoraria from Boston Scientific, Biosense Webster, St. Jude Medical, Biotronik, and Medtronic and is a consultant for Biosense Webster, St. Jude Medical, and Janssen.

Dr. Romero, Dr. Briceño, and Dr. Grushko declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Myocardial Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, J., Grushko, M., Briceño, D.F. et al. Radiofrequency Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). Curr Cardiol Rep 19, 82 (2017). https://doi.org/10.1007/s11886-017-0893-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-017-0893-3

Keywords

Navigation